首页> The Lancet. Oncology> Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

导出原文传递

翻译打印收藏纠错

第一作者： Eric,Pujade-Lauraine

第一单位： Medical Oncology Department, Université Paris Descartes, AP-HP, Paris, France. Electronic address: epujade@arcagy.org.

作者： Eric,Pujade-Lauraine ^[1] ; Jonathan A,Ledermann ^[2] ; Frédéric,Selle ^[3] ; Val,Gebski ^[4] ; Richard T,Penson ^[5] ; Amit M,Oza ^[6] ; Jacob,Korach ^[7] ; Tomasz,Huzarski ^[8] ; Andrés,Poveda ^[9] ; Sandro,Pignata ^[10] ; Michael,Friedlander ^[11] ; Nicoletta,Colombo ^[12] ; Philipp,Harter ^[13] ; Keiichi,Fujiwara ^[14] ; Isabelle,Ray-Coquard ^[15] ; Susana,Banerjee ^[16] ; Joyce,Liu ^[17] ; Elizabeth S,Lowe ^[18] ; Ralph,Bloomfield ^[19] ; Patricia,Pautier ^[20] ; SOLO2/ENGOT-Ov21 investigators

作者单位： Medical Oncology Department, Université Paris Descartes, AP-HP, Paris, France. Electronic address: epujade@arcagy.org. ^[1] Department of Oncology, University College London, London, UK. ^[2] Hôpital Tenon, Paris, France. ^[3] Department of Biostatistics and Research Methodology, University of Sydney, Sydney, NSW, Australia. ^[4] Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA. ^[5] Princess Margaret Cancer Centre, Toronto, Canada. ^[6] Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel. ^[7] Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. ^[8] Instituto Valenciano de Oncología, Valencia, Spain. ^[9] Istituto Tumori Pascale di Napoli, Naples, Italy. ^[10] Department of Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia. ^[11] Gynecology Department, University of Milan-Bicocca and Istituto Europeo Oncología, Milan, Italy. ^[12] Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany. ^[13] Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan. ^[14] Medical Oncology Department, Centre Léon Bérard and University Claude Bernard, Lyon, France. ^[15] The Royal Marsden NHS Foundation Trust, London, UK. ^[16] Dana-Farber Cancer Institute, Boston, MA, USA. ^[17] AstraZeneca, Gaithersburg, MD, USA. ^[18] AstraZeneca, Cambridge, UK. ^[19] Gustave Roussy Cancer Campus, Villejuif, France. ^[20]